Please login to the form below
Gossamer Bio
This page shows the latest Gossamer Bio news and features for those working in and with pharma, biotech and healthcare.
Novartis ditches oral asthma drug after disappointing phase 3 readout
The failure of Novartis’ drug also damages the overall hypothesis of DP2 targeting drug candidates, and particularly hurts the prospects of would-be competitor Gossamer Bio. ... If it can disprove the naysayers and bring GB001 to market in asthma,
Latest news
-
After December slump, what’s in store for biotech in 2019?
Nevertheless, Renaissance says biotech IPOs “have been getting bigger, and 2019 could see more well-funded biotechs like Gossamer Bio come public if the poor trading of high-profile Moderna does
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
